Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Cancer
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085501
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- 163 sites in United States
- Volunteers
- 242 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
This phase I/II trial tests the safety, side effects and best dose of sotorasib with trastuzumab deruxtecan and how well the combination works in treating patients with KRAS G12C mutated non-small cell lung cancer that has spread…
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07012031
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer
Cancer patients are highly variable in their body composition, specifically in the proportion of fat and muscle. Some patients tend to gain fat and lose muscle (or lean body mass) at the same time.
- Trial name
- NCT01624051
- Testing
- Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area, Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- AHS Cancer Control Alberta
Lung Cancer
Paclitaxel in Treating Patients With Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have unresectable…
- Trial name
- NCT00002972
- Testing
- paclitaxel
- Where
- 5 sites in Belgium, Czechia and 3 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC (Non-small Cell Lung Cancer)
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy…
- Trial name
- NCT06939127
- Testing
- Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy, Surgery, Adjuvant tislelizumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Colorectal Cancer
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
RATIONALE: Chemotherapy may cause blood clots to form in the thigh, leg, and lung. This study may help doctors understand how often blood clots occur in patients undergoing chemotherapy.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00433602
- Testing
- clinical observation, management of therapy complications, ultrasound imaging
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery 25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC), i.e.
- Trial name
- NVALT12 (NCT01171170)
- Testing
- carboplatin paclitaxel bevacizumab, Standard treatment plus nitroglycerin
- Where
- 8 sites in Netherlands
- Volunteers
- 223 people
- Sponsor
- Dutch Society of Physicians for Pulmonology and Tuberculosis
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Stage III NSCLC
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
This is a multi-center, open-label, randomized Phase 2 trial evaluating PDR001 in two arms for concurrent chemoradiation and consolidation in the treatment-naïve patients with locally advanced, unresectable stage III NSCLC.
- Trial name
- NCT03945227
- Testing
- standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001, PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
- Where
- South Korea
- Sponsor
- Yonsei University
Lung Cancer
S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with paclitaxel in treating patients with…
- Trial name
- NCT00002969
- Testing
- paclitaxel
- Where
- 85 sites in United States
- Volunteers
- 60 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes.
- Conditions
- Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03735095
- Testing
- Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Cognitive/Functional Effects
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
RATIONALE: Gathering information about psychological and social adjustment after radiation therapy in patients with cancer may help doctors plan the best treatment.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00905086
- Testing
- questionnaire administration, cognitive assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
Lung cancer is still the leading cause of cancer related-deaths worldwide, with an overall all-stage 5-year survival of approximately 17%. The primary treatment of early stage (I-IIIA) NSCLC is curative surgery.
- Trial name
- IONESCO (NCT03030131)
- Testing
- Durvalumab
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation…
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02444741
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will…
- Trial name
- FLINN (NCT07355205)
- Testing
- Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
Resectable Stage II-III Non-small Cell Lung Cancer
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.
- Trial name
- NCT07402070
- Testing
- IBI363
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00356941
- Testing
- docetaxel, oxaliplatin, radiation therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Carcinoma, Non Small Cell Lung
Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
- Trial name
- NCT00191256
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-small-cell Lung
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Primary objective is to assess the overall response rate (ORR) after induction therapy with docetaxel in combination with CDDP and cetuximab in patients with NSCLC stage IB, II, and IIIa.
- Trial name
- NCT00406302
- Testing
- Docetaxel, oxaliplatin, cetuximab
- Where
- 7 sites in Austria
- Volunteers
- 41 people
- Sponsor
- Wolfgang Hilbe
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.